16-fluoroestradiol has been researched along with Adenocarcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlson, KE; Chan, SR; Dence, CS; Fettig, NM; Fowler, AM; Jeyakumar, M; Katzenellenbogen, JA; Schreiber, RD; Sharp, TL; Welch, MJ; Zhou, D | 1 |
| Fujibayashi, Y; Kotsuji, F; Kurokawa, T; Okazawa, H; Sawamura, Y; Shinagawa, A; Yoshida, Y | 1 |
| Brodack, JW; Katzenellenbogen, JA; Mathias, CJ; McGuire, AH; Mintun, MA; Siegel, BA; Welch, MJ | 1 |
3 other study(ies) available for 16-fluoroestradiol and Adenocarcinoma
| Article | Year |
|---|---|
Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Blotting, Western; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Female; Fluorodeoxyglucose F18; Fulvestrant; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Neoplasm Transplantation; Norpregnenes; Positron-Emission Tomography; Predictive Value of Tests; Rabbits; Radiopharmaceuticals; Receptors, Steroid; STAT1 Transcription Factor | 2012 |
The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer.
Topics: Adenocarcinoma; Adult; Endometrial Neoplasms; Estradiol; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
Breast cancer: PET imaging of estrogen receptors.
Topics: Adenocarcinoma; Aged; Axilla; Breast Neoplasms; Estradiol; Female; Fluorine Radioisotopes; Humans; Lymphatic Metastasis; Middle Aged; Receptors, Estrogen; Tomography, Emission-Computed | 1988 |